Clotting Propensity of Surface-Treated Membranes in a Hemodialysis Set-up That Avoids Systemic Anticoagulation
- PMID: 38262850
- DOI: 10.1016/j.semnephrol.2023.151482
Clotting Propensity of Surface-Treated Membranes in a Hemodialysis Set-up That Avoids Systemic Anticoagulation
Abstract
The development of biocompatible membranes, aiming to limit the inflammatory response, oxidative stress, and coagulability during hemodialysis, has been an important step in reducing dialysis-related adverse outcomes. This includes a reduction in the risk of clotting of the extracorporeal circuit, thus enabling hemodialysis with a reduced dose or even without systemic anticoagulant drugs in patients with an increased bleeding risk. In this article, we summarize the in vitro research and clinical evidence on the antithrombotic properties of vitamin E- and heparin-coated membranes.
Keywords: Anticoagulation; dialyzer; hemodialysis; heparin-coated; membrane; vitamin E-coated.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
